-
2024-517185-42-00
3
2020-05-04
Children and teenagers with refractory/relapsing solid tumor
-
2024-514603-34-00
5
2020-03-02
intermediate-risk differentiated thyroid cancer patients
-
2024-515504-39-00
7
2020-02-09
Patients with hematological malignancies (Cf. inclusion criteria) HLA-
-
2022-501454-11-00
5
2020-02-05
standard risk ALK-positive anaplastic large cell lymphoma (ALCL)
-
2023-507256-76-00
6
2020-01-14
Ulcerative colitis
-
2023-508926-91-00
5
2019-12-05
Stage IV childhood renal tumour with pulmonary +/- non-pulmonary
metas
-
2023-507689-26-00
5
2019-10-07
Histologically or cytologically confirmed Locoregional Hepatocellular
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2023-504201-36-00
10
2018-12-21
Defined by parent protocol. The study will enroll all adult and paedia
-
2024-514780-26-00
4
2018-10-23
Patients ≤50 years old with high-risk osteosarcoma (defined as metasta
-
2024-516810-39-00
4
2018-02-13
Adjuvant therapy after salvage surgery of high risk recurrent head and
-
2023-509318-13-00
6
2018-01-15
Multiple indications
-
2023-504520-26-00
5
2017-10-19
Duchenne Muscular Dystrophy (DMD)
-
2023-508128-37-00
5
2017-07-19
All patients who have been treated with Novartis or Penn CAR T-cell th
-
2024-512827-36-00
4
2016-10-17
Penis carcinoma
-
2024-514791-40-00
9
2016-08-03
pediatric cancer
-
2024-516704-41-00
11
2016-03-30
Rheumatoid Arthritis
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)
-
2024-517275-21-00
4
2012-02-20
Retinoblastoma
-
2025-521302-17-00
10
2026-05-26
Hihg risk of cholangiocarcinoma intra hépatic resectable
-
2025-521918-26-00
4
2026-02-11
HIV Infections
-
2024-516873-57-00
10
2026-01-13
Acute myeloid leukemia in adults aged 18 to 60
-
2022-502305-15-00
7
2025-11-26
Relapsed or refractory B-cell Acute Lymphoblastic
Leukemia
-
2023-508988-73-00
5
2025-10-29
Cytomegalovirus (CMV) infection in children and adolescents who have r